Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
347.28-10.20 (-2.85%)
At close: 04:00PM EST
349.95 +2.67 (+0.77%)
After hours: 07:06PM EST
Advertisement

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
http://www.illumina.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees7,800

Key Executives

NameTitlePayExercisedYear Born
Mr. Francis A. deSouzaCEO & DirectorN/AN/A1971
Mr. Sam A. SamadChief Financial Officer716.04kN/A1970
Dr. Alexander Aravanis M.D., Ph.D.CTO & Head of Research and Product Devel.416.48kN/A1976
Ms. Susan H. TousiChief Commercial Officer655.31kN/A1969
Stephanie CamposPresN/AN/AN/A
Mr. Jose A. Torres Jr.Chief Accounting Officer & VPN/AN/A1975
Mr. Steve PhillpottSr. VP & Chief Information OfficerN/AN/AN/A
Mr. Charles E. DadswellSr. VP, Gen. Counsel & Sec.N/AN/A1959
Mr. Eric EndicottSr. Director of Corp. CommunicationsN/AN/AN/A
Dr. Joydeep Goswami M.B.A., Ph.D.Chief Strategy & Corp. Devel. OfficerN/AN/A1971
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.

Corporate Governance

Illumina, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 3; Board: 1; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement